{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Novel+Antiviral+Drug&page=2", "query": { "intervention": "Novel Antiviral Drug", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 29, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Novel+Antiviral+Drug&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Novel+Antiviral+Drug&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T10:26:18.669Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07115368", "title": "Study of GS-1219 in Participants With HIV-1", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "GS-1219", "type": "DRUG" }, { "name": "BVY", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 4, "start_date": "2025-08-11", "completion_date": "2025-10-02", "has_results": false, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-10-05T10:26:18.669Z", "location_count": 15, "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07115368" }, { "nct_id": "NCT03057236", "title": "Pilot Feasibility Study of a Cognitive Behavioral Coping Skills (CBCS) Group Intervention for Hep C Therapy Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hepatitis C", "Hepatitis C, Chronic" ], "interventions": [ { "name": "Cognitive Behavior Coping Skills", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 20, "start_date": "2014-03-01", "completion_date": "2014-12-31", "has_results": false, "last_update_posted_date": "2017-02-20", "last_synced_at": "2026-10-05T10:26:18.669Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03057236" }, { "nct_id": "NCT07300085", "title": "A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "Fluzone® High-Dose (HD) influenza vaccine", "type": "BIOLOGICAL" }, { "name": "MK-1406 Injection", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "BIOLOGICAL", "COMBINATION_PRODUCT" ], "sponsor": "Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 710, "start_date": "2025-11-08", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-05T10:26:18.669Z", "location_count": 4, "location_summary": "Glendale, California • Baltimore, Maryland", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07300085" }, { "nct_id": "NCT07225959", "title": "A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "MK-1406 Injection", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 400, "start_date": "2025-10-29", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-05T10:26:18.669Z", "location_count": 4, "location_summary": "Miami Lakes, Florida • Spartanburg, South Carolina", "locations": [ { "city": "Miami Lakes", "state": "Florida" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "Spartanburg", "state": "South Carolina" }, { "city": "Spartanburg", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07225959" }, { "nct_id": "NCT03471624", "title": "Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis B, Chronic" ], "interventions": [ { "name": "Tenofovir Alafenamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 270, "start_date": "2018-05-01", "completion_date": "2022-04-19", "has_results": true, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-10-05T10:26:18.669Z", "location_count": 2, "location_summary": "Palo Alto, California • San Jose, California", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Jose", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03471624" }, { "nct_id": "NCT01047540", "title": "Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HSV-2" ], "interventions": [ { "name": "AIC316", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AiCuris Anti-infective Cures AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 156, "start_date": "2010-03", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2023-04-21", "last_synced_at": "2026-10-05T10:26:18.669Z", "location_count": 6, "location_summary": "Miami, Florida • Indianapolis, Indiana • Portland, Oregon + 3 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Portland", "state": "Oregon" }, { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01047540" }, { "nct_id": "NCT01063829", "title": "Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HCMV Reactivation or HCMV End-Organ Disease" ], "interventions": [ { "name": "60 mg AIC246", "type": "DRUG" }, { "name": "120 mg AIC246", "type": "DRUG" }, { "name": "240 mg AIC246", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AiCuris Anti-infective Cures AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2010-03", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2018-02-13", "last_synced_at": "2026-10-05T10:26:18.669Z", "location_count": 14, "location_summary": "Los Angeles, California • Stanford, California • Denver, Colorado + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01063829" }, { "nct_id": "NCT01302847", "title": "Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DTG film-coated tablets", "type": "DRUG" }, { "name": "DTG granules for suspension", "type": "DRUG" }, { "name": "DTG dispersible tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Weeks", "maximum_age": "17 Years", "sex": "ALL", "summary": "4 Weeks to 17 Years" }, "enrollment_count": 181, "start_date": "2011-04-20", "completion_date": "2023-10-18", "has_results": true, "last_update_posted_date": "2024-12-12", "last_synced_at": "2026-10-05T10:26:18.669Z", "location_count": 17, "location_summary": "La Jolla, California • Long Beach, California • Los Angeles, California + 11 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01302847" }, { "nct_id": "NCT00001087", "title": "The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Ritonavir", "type": "DRUG" }, { "name": "Nelfinavir mesylate", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Levocarnitine", "type": "DRUG" }, { "name": "Adefovir dipivoxil", "type": "DRUG" }, { "name": "Saquinavir", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" }, { "name": "Zalcitabine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 300, "start_date": null, "completion_date": "2000-07", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-05T10:26:18.669Z", "location_count": 5, "location_summary": "Chicago, Illinois • Baltimore, Maryland • New York, New York", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001087" }, { "nct_id": "NCT03383419", "title": "Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Epclusa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 15, "start_date": "2018-03-20", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-10-05T10:26:18.669Z", "location_count": 3, "location_summary": "Los Angeles, California • Durham, North Carolina • Dallas, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03383419" } ] }